Skip to main content
NVDA+1.04%AAPL+0.02%GOOGL+0.86%MSFT+0.97%AMZN+0.82%TSM+2.75%SPCX+7.63%META+0.27%AVGO+2.08%TSLA+0.97%SKHY-0.06%MU+0.23%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.55%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.29%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.94%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.82%USDZAR-0.78%USDPLN-0.76%AUDCHF+0.68%USDMXN-0.65%USDSEK-0.58%CHFSEK-0.55%AUDJPY+0.53%GBPCHF+0.48%EURHKD+0.43%GBPTRY+0.41%USDDKK-0.40%GBPZAR-0.38%AUDUSD+0.38%EURZAR-0.37%AUDCAD+0.36%NOKJPY+0.36%GBPJPY+0.36%EURCNH+0.36%EURPLN-0.35%EURCHF+0.34%NZDMXN-0.33%AUDNZD+0.32%GBPHKD+0.32%USDNOK-0.30%GBPMXN-0.28%CHFNOK-0.28%NZDCHF+0.28%GBPCAD+0.27%GBPUSD+0.27%AUDDKK-0.26%EURSGD+0.25%EURAUD-0.25%GBPSGD+0.24%USDCHF+0.22%CADCHF+0.22%GBPNZD+0.22%SGDJPY+0.21%EURJPY+0.21%EURCZK-0.19%EURSEK-0.17%AUDNOK-0.17%NZDJPY+0.16%USDILS+0.16%NZDSGD+0.16%USDSGD-0.16%GBPAUD-0.14%EURGBP-0.14%CHFSGD-0.14%CHFJPY-0.13%EURUSD+0.12%EURCAD+0.12%USDJPY+0.12%EURNOK+0.10%USDTRY+0.10%USDTHB+0.10%CADJPY+0.10%EURNZD+0.08%NZDCAD+0.06%USDCNH-0.05%NZDUSD+0.05%USDCOP-0.04%AUDSGD-0.02%EURDKK+0.01%USDHKD+0.01%USDCAD+0.01%UKOIL-2.30%USOIL-1.92%W1+1.12%COTTON+1.03%COFFEE+0.88%C1+0.88%GAUUSD+0.82%XAUUSD+0.82%COCOA-0.81%GAGUSD+0.71%XAGUSD+0.71%S1+0.59%BTCUSD+0.57%ETHUSD+6.15%USDTUSD-0.03%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.18%ZECUSDT+2.50%DOGEUSD-1.82%XMRUSDT-0.71%LINKUSD+3.21%XLMUSD+0.55%BCHUSDT+0.41%UNIUSD-2.00%LTCUSD-4.60%SUIUSD-0.85%HBARUSDT-0.22%TONUSD+12.52%TAOUSDT-0.47%AAVEUSD-0.86%DOTUSDT+0.60%ICPUSDT-3.69%ONDOUSDT+0.24%WLDUSDT+1.00%ARBUSDT-3.14%JUPUSDT-0.14%ATOMUSDT-0.52%INJUSDT+0.96%STXUSDT+0.08%FETUSDT-1.86%SEIUSDT-0.61%PYTHUSDT+1.04%TIAUSDT-1.42%IMXUSDT-1.75%GRTUSDT-0.26%OPUSDT-2.99%WIFUSDT+0.40%IOTAUSDT+3.65%AXSUSDT-0.86%POLUSDT+1.63%FARTCOINUSDT+2.29%EOSUSDT+3.84%DYDXUSDT-1.69%GALAUSDT-0.52%ORDIUSDT+1.19%NOTUSDT+1.29%RONINUSDT+4.44%NVDA+1.04%AAPL+0.02%GOOGL+0.86%MSFT+0.97%AMZN+0.82%TSM+2.75%SPCX+7.63%META+0.27%AVGO+2.08%TSLA+0.97%SKHY-0.06%MU+0.23%BRK-B+0.32%LLY+0.02%AMD-0.34%JPM0.00%WMT+0.78%ASMLa+0.55%V+2.51%XOM+0.01%JNJ-1.21%INTC-2.63%0700.HK+1.23%MA+2.23%ABBV+1.12%1398.HK+1.61%CSCO+0.55%LRCX-0.49%AP2d+1.29%AMAT+0.41%CVX-0.11%ORCL+0.18%COST+0.31%CAT+0.32%BAC+0.47%KO+1.00%DELL-1.86%PG+0.71%UNH+1.80%0005.HK+1.93%HSBA.L+0.94%3988.HK+1.69%ARM-1.49%1816.HK+0.48%GE-1.04%0857.HK+1.04%MS-0.06%0939.HK+1.47%PM+1.10%1288.HK+0.92%PLNJPY+0.82%USDZAR-0.78%USDPLN-0.76%AUDCHF+0.68%USDMXN-0.65%USDSEK-0.58%CHFSEK-0.55%AUDJPY+0.53%GBPCHF+0.48%EURHKD+0.43%GBPTRY+0.41%USDDKK-0.40%GBPZAR-0.38%AUDUSD+0.38%EURZAR-0.37%AUDCAD+0.36%NOKJPY+0.36%GBPJPY+0.36%EURCNH+0.36%EURPLN-0.35%EURCHF+0.34%NZDMXN-0.33%AUDNZD+0.32%GBPHKD+0.32%USDNOK-0.30%GBPMXN-0.28%CHFNOK-0.28%NZDCHF+0.28%GBPCAD+0.27%GBPUSD+0.27%AUDDKK-0.26%EURSGD+0.25%EURAUD-0.25%GBPSGD+0.24%USDCHF+0.22%CADCHF+0.22%GBPNZD+0.22%SGDJPY+0.21%EURJPY+0.21%EURCZK-0.19%EURSEK-0.17%AUDNOK-0.17%NZDJPY+0.16%USDILS+0.16%NZDSGD+0.16%USDSGD-0.16%GBPAUD-0.14%EURGBP-0.14%CHFSGD-0.14%CHFJPY-0.13%EURUSD+0.12%EURCAD+0.12%USDJPY+0.12%EURNOK+0.10%USDTRY+0.10%USDTHB+0.10%CADJPY+0.10%EURNZD+0.08%NZDCAD+0.06%USDCNH-0.05%NZDUSD+0.05%USDCOP-0.04%AUDSGD-0.02%EURDKK+0.01%USDHKD+0.01%USDCAD+0.01%UKOIL-2.30%USOIL-1.92%W1+1.12%COTTON+1.03%COFFEE+0.88%C1+0.88%GAUUSD+0.82%XAUUSD+0.82%COCOA-0.81%GAGUSD+0.71%XAGUSD+0.71%S1+0.59%BTCUSD+0.57%ETHUSD+6.15%USDTUSD-0.03%XRPUSD-0.54%SOLUSD-2.00%TRXUSDT-0.18%ZECUSDT+2.50%DOGEUSD-1.82%XMRUSDT-0.71%LINKUSD+3.21%XLMUSD+0.55%BCHUSDT+0.41%UNIUSD-2.00%LTCUSD-4.60%SUIUSD-0.85%HBARUSDT-0.22%TONUSD+12.52%TAOUSDT-0.47%AAVEUSD-0.86%DOTUSDT+0.60%ICPUSDT-3.69%ONDOUSDT+0.24%WLDUSDT+1.00%ARBUSDT-3.14%JUPUSDT-0.14%ATOMUSDT-0.52%INJUSDT+0.96%STXUSDT+0.08%FETUSDT-1.86%SEIUSDT-0.61%PYTHUSDT+1.04%TIAUSDT-1.42%IMXUSDT-1.75%GRTUSDT-0.26%OPUSDT-2.99%WIFUSDT+0.40%IOTAUSDT+3.65%AXSUSDT-0.86%POLUSDT+1.63%FARTCOINUSDT+2.29%EOSUSDT+3.84%DYDXUSDT-1.69%GALAUSDT-0.52%ORDIUSDT+1.19%NOTUSDT+1.29%RONINUSDT+4.44%
1G

10x Genomics, Inc. (TXG)

NASDAQ • Healthcare

$97.74
+$4.23 (+4.5%)
Market closed

Last close at October 5, 2026 at 20:00 UTC

Open$93.5
Day Range$92.26 - $98.32
Avg. Volume (3M)3.2M
Market Cap$12.4B
52 Week Range
$11.16$98.32
Next EarningsIn 30 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$151M100%
Gross Profitminus cost of goods$112.4M74%

In plain terms: out of every $100 in revenue, 10x Genomics, Inc. currently loses $12.

Fundamentals & Financials

Revenue (TTM)
$616.9M
Net Income (TTM)
-$75.1M
EPS (TTM)
-$0.59
ROA (TTM)
-7.29%
Current Ratio
5.69

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+31.6%Q1 2026-$0.13
+65.5%Q2 2026-$0.1
+42.4%Q3 2026-$0.14
Next

Nov 5

in 30 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +42.4%

10x Genomics beat expectations on both the top and bottom line, even as revenue declined year over year in the second fiscal quarter of 2026, reported August 6, 2026. Revenue fell 12.6% to about $151.0 million (from $172.9 million a year ago) but still topped consensus at $151.0 million versus the $146.7 million estimate, +3%. EPS of -$0.14 also topped the -$0.24 estimate by $0.10, swinging from $0.28 a year ago, while net income was a loss of roughly $17.9 million compared with $34.5 million a year ago. Profitability held up at the gross line, with gross profit of about $112.5 million translating to a gross margin of roughly 75%, while operating results remained negative with operating income of about -$19.6 million and operating margin near -13%. The company generated about $17.0 million of operating cash flow. Consensus for the next period calls for EPS of -$0.27 on revenue of $147.3 million.

Next report — what to expect

10x Genomics, Inc. (TXG) reports on November 5, 2026. Wall Street is looking for consensus EPS of -$0.262 on consensus revenue of $147.8 million. For trailing context, revenue declined -12.6% year over year last quarter. The company has beaten EPS in 6 of its 8 most recent quarters.

View full earnings history

About 10x Genomics, Inc.

10x Genomics, Inc. (NASDAQ: TXG) develops life-science tools and software for biological analysis, with a business centered on single-cell and spatial genomics in the healthcare technology field. Its revenue was $642.8 million in FY2025. The company sells instruments, consumables, and analysis software under brands including Chromium, Chromium Connect, and Visium.

Name
10x Genomics, Inc.
CEO
Serge Saxonov
Website
www.10xgenomics.com
Industry
Healthcare
Year Founded
2012
Employees
1,178

Today's Snapshot

AI-generated

TXG closed 4.5% higher at 97.74, in line with a firmer sector. At the close, TXG was within 0.6% of its 52-week high of 98.30.

Trading Volume

Below 10d avg (3.4M)

2.8M

vs S&P 500 Today

Strong Outperformance

+3.77%

Updated: October 5, 2026 at 20:03 UTC

TXG Headlines

Cancer vaccine data lifts biotech shares

September 13, 2026

3 min read
View All News

Technical Indicators

6 Buy0 Neutral2 Sell
TXG exhibits a strong buy signal driven by powerful trend and momentum confluence while volume confirms the move. The stock is trading well above short- and long-term averages and above a classic pivot near 92.07, MACD and CCI indicate robust bullish momentum, and ADX signals a strong directional trend. Some oscillators show overbought readings and ATR indicates elevated volatility, but on‑balance volume remains supportive, reinforcing the advance. Technical takeaway: Strong Buy.
All signals
  • EMA (5 indicators)$40.33 - $88.07
    Buy
  • RSI (14)79.71
    Sell
  • Stochastic %K (14, 3, 3)90.06
    Sell
  • MACD Level (12, 26)8.38
    Buy

Peers & Related Assets

GRDNGuardian Pharmacy Services, Inc.
$42.1-0.7%
SDGRSchrödinger, Inc.
$32.6+7.6%
PGNYProgyny, Inc.
$25.86+2.5%
NUVBNuvation Bio Inc.
$4.95-3.7%
OMCLOmnicell, Inc.
$34.64+3.1%
CERTCertara, Inc.
$10.07+7.6%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.